Quick Overview
- Analysts project Q1 EPS at $6.05 alongside revenue of $9.76 billion, representing 3.1% growth versus the prior-year quarter
- Wall Street maintains a Buy rating consensus with an average price target of $736.24, suggesting approximately 11% potential appreciation from current levels near $665
- Primary focus: profitability improvement, with segment operating margins anticipated to reach roughly 11%
- Latest program developments feature a $475M Glide Phase Interceptor contract adjustment and successful YFQ-48A Talon Blue drone engine test
- Shares have declined 2% during the past 30 days while the aerospace and defense industry advanced 10.3%
Northrop Grumman unveils Q1 2026 financial results Tuesday morning before market open. Following an extended period of substantial development investment, shareholders are focused on a critical question: has the anticipated margin improvement materialized?
Northrop Grumman Corporation, NOC
Analyst consensus calls for earnings per share of $6.05 paired with revenue of $9.76 billion. These figures represent a sequential decrease from Q4’s $7.23 EPS and $11.7 billion revenue performance, though this pattern aligns with industry norms. Defense industry companies routinely deliver their most robust quarterly results during the final three months of the fiscal year.
Compared to the same period last year, revenue projections indicate 3.1% expansion. This outlook represents a meaningful shift from the 6.6% revenue contraction Northrop experienced during Q1 of the previous year.
During the prior quarter, the company surpassed expectations on both top-line and operating income metrics. Revenue reached $11.71 billion, climbing 9.6% year over year. Earnings per share landed at $7.23, exceeding the $6.99 Wall Street consensus. The single area of concern involved full-year EPS guidance, which came in below analyst projections.
Shares currently trade in the $665–$667 range, positioned near the midpoint of the 52-week span from $450.13 to $774.00. Analyst price objectives have shown upward momentum. Wells Fargo launched coverage with a Buy recommendation and $800 target on March 31. Deutsche Bank elevated its target to $778 on April 8. Jefferies adjusted its Hold-rated target upward to $710 on April 9.
EPS forecasts have increased 0.51% during the past 60 days. Revenue projections have risen 0.24%. While the magnitude remains modest, the trajectory points in a favorable direction.
Profitability Improvement Takes Priority
The central issue entering Tuesday’s report centers on whether margin enhancement is materializing in actual financial performance. Analysts anticipate segment operating margins will climb to approximately 11%.
The Aeronautics division benefits from cycling past a B-21 Raider development charge recorded in the year-ago period, which should provide tailwinds. Mission Systems stands to gain from an improved program portfolio composition. Positive results from both business units would indicate that Northrop’s capital-intensive development phase is transitioning toward a more profitable stage.
Full-year earnings guidance remains another area of interest. The existing range spans $27.40 to $27.90. Analysts anticipate management will maintain that outlook, though several observers believe the more substantial growth opportunity unfolds in 2027.
Contract Announcements Set the Stage
Northrop has experienced an active April regarding contract activity. The defense prime secured a $475 million program modification to accelerate its Glide Phase Interceptor initiative. The YFQ-48A Talon Blue autonomous combat aircraft successfully completed its inaugural engine run on April 17. The Sentinel ICBM program continues progressing toward an initial flight scheduled for 2027.
Shares have fallen roughly 2% over the trailing month. The wider aerospace and defense sector has gained 10.3% during the identical timeframe, positioning Northrop among the weaker performers within its industry group approaching the earnings announcement.
Industry peers have already released their quarterly results. AAR delivered 24.6% revenue growth while topping estimates, with shares surging 9.9%. Byrna achieved 10.9% growth but fell short of expectations, with shares declining 38.3%.
Analysts have maintained relatively stable estimates throughout the last 30 days, indicating limited anticipation of significant positive or negative surprises.
